[^99mTc]Tc-PSMA-HSG for PSMA-targeted Hybrid Surgical Guidance: a new addition to the PSMA-I&S/I&T family

Margret Schottelius^{1

2

3}, David Viertl⁴, Tessa Buckle⁵, Hélène Koch^{4

6

7}, Sebastian Martin^{4

6

7}, Alexandra Litvinenko^{4

6

7}, Marianne Patt⁸, D M van Willigen⁵, Fijs W B van Leeuwen⁵, Hans-Jürgen Wester⁹, Dorothea Weckermann¹⁰, Alessandro Liebich⁸, Alexander Gäble⁸, Nic G Reitsam^{11

12}, Bruno Märkl^{11

12}, Johanna S Enke^{8

12}, Julia Brosch-Lenz^{8

13}, Constantin Lapa^{8

12}

Affiliations

¹ Translational Radiopharmaceutical Sciences, Department of Nuclear Medicine, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, 1011, Switzerland. margret.schottelius@chuv.ch.
² AGORA, Pôle de recherche sur le cancer, Lausanne, 1011, Switzerland. margret.schottelius@chuv.ch.
³ SCCL Swiss Cancer Center Leman, Lausanne, 1011, Switzerland. margret.schottelius@chuv.ch.
⁴ Translational Radiopharmaceutical Sciences, Department of Nuclear Medicine, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, 1011, Switzerland.
⁵ Interventional Molecular Imaging Laboratory, Leiden University Medical Center, Leiden, 2333 ZA, The Netherlands.
⁶ AGORA, Pôle de recherche sur le cancer, Lausanne, 1011, Switzerland.
⁷ SCCL Swiss Cancer Center Leman, Lausanne, 1011, Switzerland.
⁸ Nuclear Medicine, University of Augsburg, 86156, Augsburg, Germany.
⁹ Chair for Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Technische Universität München, 85748, Garching, Germany.
¹⁰ Urology, Medical Faculty, University of Augsburg, 86156, Augsburg, Germany.
¹¹ Pathology, Medical Faculty, University of Augsburg, 86156, Augsburg, Germany.
¹² Bavarian Center for Cancer Research, 86156, Augsburg, Augsburg, Germany.
¹³ Institute of Nuclear Medicine, Glen Burnie, MD, USA.

PMID: 41233512
DOI: 10.1007/s00259-025-07623-2

[^99mTc]Tc-PSMA-HSG for PSMA-targeted Hybrid Surgical Guidance: a new addition to the PSMA-I&S/I&T family

Margret Schottelius et al. Eur J Nucl Med Mol Imaging. 2025.

. 2025 Nov 14.

doi: 10.1007/s00259-025-07623-2. Online ahead of print.

Authors

Affiliations

¹ Translational Radiopharmaceutical Sciences, Department of Nuclear Medicine, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, 1011, Switzerland. margret.schottelius@chuv.ch.
² AGORA, Pôle de recherche sur le cancer, Lausanne, 1011, Switzerland. margret.schottelius@chuv.ch.
³ SCCL Swiss Cancer Center Leman, Lausanne, 1011, Switzerland. margret.schottelius@chuv.ch.
⁴ Translational Radiopharmaceutical Sciences, Department of Nuclear Medicine, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, 1011, Switzerland.
⁵ Interventional Molecular Imaging Laboratory, Leiden University Medical Center, Leiden, 2333 ZA, The Netherlands.
⁶ AGORA, Pôle de recherche sur le cancer, Lausanne, 1011, Switzerland.
⁷ SCCL Swiss Cancer Center Leman, Lausanne, 1011, Switzerland.
⁸ Nuclear Medicine, University of Augsburg, 86156, Augsburg, Germany.
⁹ Chair for Pharmaceutical Radiochemistry, Faculties of Chemistry and Medicine, Technische Universität München, 85748, Garching, Germany.
¹⁰ Urology, Medical Faculty, University of Augsburg, 86156, Augsburg, Germany.
¹¹ Pathology, Medical Faculty, University of Augsburg, 86156, Augsburg, Germany.
¹² Bavarian Center for Cancer Research, 86156, Augsburg, Augsburg, Germany.
¹³ Institute of Nuclear Medicine, Glen Burnie, MD, USA.

PMID: 41233512
DOI: 10.1007/s00259-025-07623-2

Abstract

Purpose: To develop a dual-labeled PSMA-targeted tracer for radio- and fluorescence-guided surgery (RGS/FGS) with enhanced clinical utility due to optimized pharmacokinetics and tumor targeting.

Methods: Four novel hybrid PSMA ligands with varying cyanine-based fluorophores were comprehensively characterized preclinically. On the basis of its excellent in vitro (logD, plasma protein binding, PSMA-affinity, internalization) and in vivo (stability, clearance kinetics, tumor uptake in LNCaP and PC3-PIp tumor-bearing mice) profile, [^99mTc]Tc-PSMA-HSG was selected as the clinical lead compound. Five patients with primary and recurrent prostate cancer underwent [^99mTc]Tc-PSMA-HSG SPECT/CT and RGS. Tracer dosimetry was calculated using a MIRDcalc v1.22 protocol.

Results: The PSMA affinity (IC₅₀=38.4 ± 5.3 nM), hydrophilicity (logD =-2.94), and human plasma protein binding of [^99mTc]Tc-PSMA-HSG were all nearly identical to those of the non-fluorescent parent compound [^99mTc]Tc-PSMA-I&S. Tumor uptake in mice was 11.8 ± 1.5%ID/g at 6 h p.i. (vs. 6.4 ± 1.0%ID/g for [^99mTc]Tc-PSMA-I&S). In and ex vivo fluorescence imaging in mice confirmed tumor localization with high signal-to-background ratios. In patients, [^99mTc]Tc-PSMA-HSG showed faster clearance and less background uptake than [^99mTc]Tc-PSMA-I&S, with notably reduced salivary gland and intestinal accumulation, but a slightly higher whole body effective dose (0.011 ± 0.003 vs. 0.0052 mSv/MBq). Intraoperative gamma detection revealed lymph node metastases in 6/6 tracer-avid lesions, which were confirmed by PSMA-HSG fluorescence microscopy and histopathology. The specificity, selectivity, NPV and PPV of [^99mTc]Tc-PSMA-HSG in RGS were 100%, respectively.

Conclusions: The hybrid tracer [^99mTc]Tc-PSMA-HSG demonstrates high specificity and favorable pharmacokinetics. Its successful first-in-human application highlights its translational potential for precise intraoperative detection of PSMA-positive lymph node metastases.

Keywords: Fluorescence guided surgery; Hybrid tracer; PSMA; Prostate cancer (PCa); Radioguided surgery.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: The study was conducted in accordance with the Declaration of Helsinki. Retrospective analysis was approved by the responsible local Ethics Committee of Ludwig-Maximilians-University Munich, Munich, Germany (reference 25-0653). Informed consent statement Informed consent was obtained from all subjects involved in the study. Consent to participate: The study was conducted in accordance with the Declaration of Helsinki and its amendments. The administration of [99mTc]Tc-PSMA-HSG complied with the German Medicinal Products Act, Arzneimittelgesetz § 13.2b, and the responsible regulatory bodies. All patients gave written informed consent prior to injection of the radiotracer. This retrospective evaluation was approved by the local ethics committee of the Ludwig-Maximilians-University Munich (reference number: 25–0493). Consent to publish: The authors affirm that human research participants provided informed consent for publication of the images in Figure(s) 6 and 7. Competing interests: The authors have no relevant financial or non-financial interests to disclose.

References

1. van der Poel HG, Buckle T, Brouwer OR, Valdes Olmos RA, van Leeuwen FW. Intraoperative laparoscopic fluorescence guidance to the Sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol. 2011;60:826–33. https://doi.org/10.1016/j.eururo.2011.03.024 . - DOI - PubMed
1. Dell’Oglio P, de Vries HM, Mazzone E, KleinJan GH, Donswijk ML, van der Poel HG, et al. Hybrid indocyanine green-(99m)Tc-nanocolloid for single-photon emission computed tomography and combined radio- and fluorescence-guided sentinel node biopsy in penile cancer: results of 740 inguinal basins assessed at a single institution. Eur Urol. 2020;78(6):865–72. https://doi.org/10.1016/j.eururo.2020.09.007 . - DOI - PubMed
1. Mazzone E, Dell’Oglio P, Grivas N, Wit E, Donswijk M, Briganti A, et al. Diagnostic value, oncologic outcomes, and safety profile of image-guided surgery technologies during robot-assisted lymph node dissection with sentinel node biopsy for prostate cancer. J Nucl Med. 2021;62:1363–71. https://doi.org/10.2967/jnumed.120.259788 . - DOI - PubMed - PMC
1. Meershoek P, KleinJan GH, van Willigen DM, Bauwens KP, Spa SJ, van Beurden F, et al. Multi-wavelength fluorescence imaging with a Da Vinci Firefly-a technical look behind the scenes. J Robot Surg. 2021;15:751–60. https://doi.org/10.1007/s11701-020-01170-8 . - DOI - PubMed
1. Dell’Oglio P, Meershoek P, Maurer T, Wit EMK, van Leeuwen PJ, van der Poel HG, et al. A drop-in gamma probe for robot-assisted radioguided surgery of lymph nodes during radical prostatectomy. Eur Urol. 2021;79:124–32. https://doi.org/10.1016/j.eururo.2020.10.031 . - DOI - PubMed

LinkOut - more resources

Full Text Sources
- Springer
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

[^99mTc]Tc-PSMA-HSG for PSMA-targeted Hybrid Surgical Guidance: a new addition to the PSMA-I&S/I&T family

Affiliations

[^99mTc]Tc-PSMA-HSG for PSMA-targeted Hybrid Surgical Guidance: a new addition to the PSMA-I&S/I&T family

Authors

Affiliations

Abstract

Conflict of interest statement

References

LinkOut - more resources

Full Text Sources

Miscellaneous